Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00362414 · ClinicalTrials.gov registry record · Phase 2
Beta-hCG + Erythropoietin in Acute Stroke
A Phase 2 study of Acute Stroke, sponsored by University of California, Irvine.
- Completed
- Registry status
- Phase 2
- Development phase
- 15
- Enrollment target
- 1
- Study location
NCT00362414 is a Phase 2 study of Acute Stroke that has completed, run by University of California, Irvine. The registered enrollment target is 15 participants, below the 6,124-participant average among 10 other Acute Stroke trials with a reported enrollment target (100% lower). The trial reports 1 study location across 1 state.
The verdict
NCT00362414, a Phase 2 study of Acute Stroke, has completed, sponsored by University of California, Irvine.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 15 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to assess the safety of Beta-hCG + Erythropoietin in patients with acute ischemic stroke.
Conditions Studied
Interventions
- DRUG Dual Growth Factor
Study Locations (1)
California
- University of California, Irvine Medical Center - Orange
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 15 participants |
| Start Date | 2006-08 |
| Est. Completion | 2008-03 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00362414
The ClinicalTrials.gov registry entry for NCT00362414 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 15 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 6,124-participant average among 10 other Acute Stroke trials with a reported enrollment target (100% lower). The listed sponsor is University of California, Irvine, which has 368 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Acute Stroke appearing as the primary indexed condition, and to 1 intervention - of which Dual Growth Factor is the first listed.
NCT00362414 reports 1 study location spanning 1 distinct geographic area - top geographies include California.
Frequently Asked Questions
What is clinical trial NCT00362414 about?
NCT00362414 is a clinical study titled "Beta-hCG + Erythropoietin in Acute Stroke". The purpose of this study is to assess the safety of Beta-hCG + Erythropoietin in patients with acute ischemic stroke.
What is the current status of trial NCT00362414?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 15 participants. The study started on 2006-08. Estimated completion is 2008-03.
What conditions does trial NCT00362414 study?
This clinical trial studies the following conditions: Acute Stroke.
What interventions are being tested in trial NCT00362414?
The interventions under investigation include: Dual Growth Factor (DRUG).
Who is sponsoring clinical trial NCT00362414?
This trial is sponsored by University of California, Irvine, which has 368 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00362414 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Acute Stroke
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Treatment of Acute Ischemic Stroke (ReMEDy2 Trial)
RECRUITING · Phase 2
-
Robot Assisted Upper Limb Neuro-Rehabilitation
COMPLETED · Phase 2
-
Blood Pressure After Endovascular Stroke Therapy-II
COMPLETED · Phase 2
-
Ischemic Conditioning During Air tRansport Save penUmbral Tissue
RECRUITING · NA
-
Stroke Recovery Initiative - Registry for Stroke Research Studies
RECRUITING
-
SEACOAST 1- SEdAtion With COllAteral Support in Endovascular Therapy for Acute Ischemic Stroke
RECRUITING · NA
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.